To control plant diseases caused by Xanthomonas spp., a novel bacteriophage exhibiting bacteriolysis activity specifically on Xanthomonas spp. was isolated. Thus, developed and provided is a plant disease control composition containing the bacteriophage as an active ingredient. Provided are a bacteriolytic agent containing a bacteriophage that has a novel genomic DNA sequence and exhibits bacteriolysis activity specifically on Xanthomonas spp., and a plant disease control composition containing the same as an active ingredient.

To control plant diseases caused by Xanthomonas spp., a novel bacteriophage exhibiting bacteriolysis activity specifically on Xanthomonas spp. was isolated. Thus, developed and provided is a plant disease control composition containing the bacteriophage as an active ingredient. Provided are a bacteriolytic agent containing a bacteriophage that has a novel genomic DNA sequence and exhibits bacteriolysis activity specifically on Xanthomonas spp., and a plant disease control composition containing the same as an active ingredient.

The technology described herein is directed to engineered MCP proteins and engineered PCP proteins, which are degraded when the proteins are not bound to an MS2 or PP7 RNA hairpin loop, respectively. Also described herein are fusion proteins comprising such engineered MCP proteins and engineered PCP proteins linked to various effector proteins. The linkage to the effector proteins can be modulated through of specialized linker domains. In addition, described herein are complexes and systems comprising the fusion proteins in combination with synthetic RNA molecules, in order to modulate the structure and/or function the synthetic RNA molecules.

The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life cycle. The invention further relates to methods for lysing certain bacteria using lysin, which are useful for example in a diagnostic procedure designed to detect these bacteria.

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

The present disclosure provides methods and compositions for modifying the genomes of bacteriophages, in particular by integrating a coding sequence for an anti-CRISPR protein into the bacteriophage genome together with a desired modification such as a deletion, insertion, or nucleotide substitution, and selecting for bacteriophages with the integrated anti-CRISPR coding sequence by introducing the phage into a counter selection strain comprising an RNA-targeting CRISPR-Cas system.

Provided herein are probiotic vaccines comprising, a recombinant filamentous phage genome comprising a nucleic acid encoding a polypeptide comprising an exogenous peptide epitope, or fragments or variants thereof, selected from the group consisting of: LPESFDGDPASNTAPLQPEQLQVF SEQ ID NO:1; HER2. In particular embodiments of the invention vaccine, the exogenous peptide epitope is functionally expressed on a coat protein selected from the group consisting of: pill, pVI, pVII, pVIII and pIX. Also provided herein are methods of preventing or treating cancer, comprising administering to a patient in need thereof, one or more of the probiotic vaccines provided herein: or one or more of the recombinant phages provided herein

Hybrid nanopores, comprising a protein pore supported within a solid-state membrane, which combine the robust nature of solid-state membranes with the easily tunable and precise engineering of protein nanopores. In an embodiment, a lipid-free hybrid nanopore comprises a water soluble and stable, modified portal protein of the Thermus thermophilus bacteriophage G20c, electrokinetically inserted into a larger nanopore in a solid-state membrane. The hybrid pore is stable and easy to fabricate, and exhibits low peripheral leakage, allowing sensing and discrimination among different types of biomolecules.

Systems and methods for editing bacteriophages are described herein.

Disclosed herein are protein-RNA display constructs that couple a protein of interest to its encoding mRNA. An example protein-RNA display construct includes a first nucleotide portion including an RNA that forms hairpin structures; a second nucleotide portion including an mRNA encoding a protein of interest; a first protein portion including a protein having RNA hairpin binding peptides that can specifically bind to the RNA hairpin structures; and a second protein portion including the protein of interest. The protein-RNA display constructs take advantage of binding interactions between RNA hairpin structures and RNA hairpin binding peptides to stably couple the protein of interest to its encoding mRNA. Also disclosed are nucleic acids encoding the protein-RNA display constructs, libraries and kits including the protein-RNA display constructs, and methods of using the protein-RNA display constructs in high-throughput display applications.